SOPHARMA AD: Publishing of Annual individual audited financial statement for 2025

POLISH FINANCIAL SUPERVISION AUTHORITY

UNI - EN REPORT No

/

2026

Date of issue:

2026-03-30

Short name of the issuer

SOPHARMA AD

Subject

Publishing of Annual individual audited financial statement for 2025

Official market - legal basis

Art. 56. 1. 2 of Act on Public Offering

Unofficial market - legal basis

Contents of the report:

Sofia, Bulgaria, 30 March 2026 – According to the requirements of art. 100n of LPOS, “Sopharma” AD (SFA: “BSE-Sofia” AD, SPH: Warsaw Stock Exchange) presents the Annual Audited Individual Financial Statements, which contains:

• XHTML format of the report in accordance with the requirements of Commission Delegated Regulation (EU) 2018/815 of 17 December 2018 supplementing Directive 2004/109/EC of the European Parliament and of the Council with regulatory technical standards on the definition of a common electronic format for reports. It contains:

- Annual financial statements according to IFRS;

- Notes to the annual financial statements;

- Annual management report and non-financial declaration;

- Corporate governance Declaration;

- Report on the implementation of the remuneration policy;

- Declaration by the responsible persons;

- Audit report; and

- Audit declaration.

• Annual reports according to a template determined by the Deputy Chairman of the Financial Supervision Commision;

• Corporate Governance Scorecard;

• Electronic reference to the published inside information under Article 7 of Regulation (EU) №596 / 2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (Market Abuse Regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC (OJ L 173/1 of 12 June 2014) (Regulation (EU) № 596/2014) on the circumstances during the past year:

http://www.x3news.com/?page=News&uniqid=6242d3eba9dc7

https://www.sopharmagroup.com/en/home/investors/investor-news/public-disclosure-of-inside-information-in-compliance-with-article-17-of-regulation-eu-no-596-2014-on-market-abuse

Annexes

File

Description

097900BGGW0000048796-20251231-EN-SEP.rar

Publishing of Annual individual audited financial statement for 2025

SOPHARMA AD

(fullname of the issuer)

SOPHARMA AD

Farmaceutyczny (far)

(short name of the issuer)

(sector according to clasification

of the WSE in Warsow)

1220

Sofia

(post code)

(city)

IlienskoShosse

(street)

(number)

+359 2 813 42 00

+359 2 936 02 86

(phone number)

(fax)

(e-mail)

(web site)

nd

(NIP)

(REGON)

SIGNATURE OF PERSONS REPRESENTING THE COMPANY

2026-03-30

Ognian Ivanov Donev

Executive Director